Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alder Biopharmaceuticals Inc stock logo
ALDR
Alder Biopharmaceuticals
$18.88
$18.88
$8.39
$19.12
$1.58B2.645.12 million shsN/A
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
$69.31
-5.6%
$72.79
$29.42
$117.33
$7.78B0.161.18 million shs1.45 million shs
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
$112.56
-1.0%
$108.01
$81.74
$129.90
$2.19B0.84117,993 shs109,742 shs
Tricida, Inc. stock logo
TCDA
Tricida
$0.13
$0.09
$13.85
$6.01M0.2217.62 million shs31.13 million shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alder Biopharmaceuticals Inc stock logo
ALDR
Alder Biopharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
+0.25%-1.18%-6.01%-20.16%+125.92%
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
-0.41%-1.12%+10.19%+8.45%+34.92%
Tricida, Inc. stock logo
TCDA
Tricida
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Alder Biopharmaceuticals Inc stock logo
ALDR
Alder Biopharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
4.7096 of 5 stars
3.51.00.04.22.84.21.9
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
4.7321 of 5 stars
3.53.00.04.41.63.31.9
Tricida, Inc. stock logo
TCDA
Tricida
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alder Biopharmaceuticals Inc stock logo
ALDR
Alder Biopharmaceuticals
0.00
N/AN/AN/A
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
3.00
Buy$138.2599.47% Upside
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
3.00
Buy$146.1429.84% Upside
Tricida, Inc. stock logo
TCDA
Tricida
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest ALDR, LGND, TCDA, and CORT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/9/2025
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$142.00 ➝ $145.00
5/6/2025
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$135.00
5/6/2025
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$150.00 ➝ $145.00
4/10/2025
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$143.00
4/3/2025
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$128.00 ➝ $131.00
4/1/2025
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$130.00 ➝ $142.00
(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alder Biopharmaceuticals Inc stock logo
ALDR
Alder Biopharmaceuticals
$1.62M977.10N/AN/A$1.61 per share11.73
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
$675.04M10.89$1.17 per share59.10$6.49 per share10.68
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
$167.13M12.99$1.59 per share70.75$43.95 per share2.56
Tricida, Inc. stock logo
TCDA
Tricida
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alder Biopharmaceuticals Inc stock logo
ALDR
Alder Biopharmaceuticals
-$296.43M-$4.87N/AN/AN/AN/A-226.13%-66.86%N/A
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
$141.21M$1.1659.7537.46N/A19.33%20.40%16.64%8/4/2025 (Estimated)
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
-$4.03M-$7.12N/A30.34N/A-73.07%-7.83%-6.92%8/5/2025 (Estimated)
Tricida, Inc. stock logo
TCDA
Tricida
-$176.57M-$2.36N/AN/AN/AN/AN/A-103.81%N/A

Latest ALDR, LGND, TCDA, and CORT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
$1.23$1.33+$0.10-$2.21$37.84 million$45.33 million
5/5/2025Q1 2025
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
$0.17$0.17N/A$0.17$177.93 million$157.21 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Alder Biopharmaceuticals Inc stock logo
ALDR
Alder Biopharmaceuticals
N/AN/AN/AN/AN/A
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
N/AN/AN/AN/AN/A
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
N/AN/AN/AN/AN/A
Tricida, Inc. stock logo
TCDA
Tricida
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alder Biopharmaceuticals Inc stock logo
ALDR
Alder Biopharmaceuticals
1.74
8.94
8.94
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
N/A
3.07
2.96
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
N/A
5.27
5.02
Tricida, Inc. stock logo
TCDA
Tricida
N/A
4.87
4.87

Institutional Ownership

CompanyInstitutional Ownership
Alder Biopharmaceuticals Inc stock logo
ALDR
Alder Biopharmaceuticals
N/A
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
93.61%
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
91.28%
Tricida, Inc. stock logo
TCDA
Tricida
N/A

Insider Ownership

CompanyInsider Ownership
Alder Biopharmaceuticals Inc stock logo
ALDR
Alder Biopharmaceuticals
15.40%
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
20.50%
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
7.00%
Tricida, Inc. stock logo
TCDA
Tricida
35.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alder Biopharmaceuticals Inc stock logo
ALDR
Alder Biopharmaceuticals
20283.84 millionN/AOptionable
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
300106.04 million84.31 millionOptionable
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
8019.29 million17.94 millionOptionable
Tricida, Inc. stock logo
TCDA
Tricida
5755.67 million35.85 millionNot Optionable

Recent News About These Companies

Tricida CEO to Pay $14 Million in Class Suit Over Drug Progress
Patrick G Enright's Net Worth
Tricida Inc (TCDAQ)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Alder Biopharmaceuticals stock logo

Alder Biopharmaceuticals NASDAQ:ALDR

Alder BioPharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It discovers, develops, and commercializes therapeutic antibodies to transform the treatment paradigm for patients with migraine in the United States, Australia, and Ireland. The company's lead product candidate is eptinezumab, a monoclonal antibody (mAb) inhibiting calcitonin gene-related peptide, which is in the late-stage clinical development for the prevention of migraine. It also develops ALD1910, a preclinical mAb that inhibits pituitary adenylate cyclase-activating polypeptide-38 for migraine prevention; and Clazakizumab, a mAb inhibiting the pro-inflammatory cytokine interleukin-6 that has completed two Phase 2b clinical trials. The company has strategic collaboration with CSL Limited for the development of clazakizumab as a therapeutic option for solid organ transplant rejection. Alder BioPharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Bothell, Washington.

Corcept Therapeutics stock logo

Corcept Therapeutics NASDAQ:CORT

$69.31 -4.09 (-5.57%)
Closing price 04:00 PM Eastern
Extended Trading
$70.69 +1.38 (+2.00%)
As of 07:16 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

Ligand Pharmaceuticals stock logo

Ligand Pharmaceuticals NASDAQ:LGND

$112.56 -1.12 (-0.99%)
Closing price 04:00 PM Eastern
Extended Trading
$112.63 +0.07 (+0.06%)
As of 04:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.

Tricida stock logo

Tricida NASDAQ:TCDA

Tricida, Inc. is a pharmaceutical company. It focuses on the development and commercialization of its product, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease. The company was founded by Gerrit Klaerner and Craig Jon Hawker on May 22, 2013 and is headquartered in South San Francisco, CA.